Malignant neoplasm of prostate
In Malignant neoplasms of male genital organs (C60-C63), chapter 2: Neoplasms
- C61 is billable and valid on claims for FY 2027. If the record has more detail, check the other codes under C60-C63 below.
- As a secondary diagnosis it is not a CC or MCC, so it doesn't raise the MS-DRG payment.
- Counts toward HCC 23 (Prostate, Breast, and Other Cancers and Tumors) in the Medicare Advantage risk model (CMS-HCC V28).
- AHRQ's Chronic Condition Indicator classes it as chronic: expected to last 12 months or longer and to limit daily life or need ongoing care.
- 34,815 US deaths in 2024 had an underlying cause in category C61, per the National Vital Statistics System on CDC WONDER. Death records use WHO ICD-10, so the count is for the whole category.
Also indexed as: Adenocarcinoma, duct, unspecified site, male; Carcinoma, endometrioid, unspecified site, male; Cystadenocarcinoma, endometrioid, unspecified site, male
Advertisements
Instructional notes
Excludes1: not coded here, use a different code
- malignant neoplasm of seminal vesicle (C63.7)
Use additional code: add a second code for this, listed after this one
- code, if applicable, to identify:
- hormone sensitivity status (Z19.1-Z19.2)
- rising PSA following treatment for malignant neoplasm of prostate (R97.21)
Also applies, from Malignant neoplasms of male genital organs (C60-C63)
These notes sit on C60-C63 and apply to every code under it, including C61.
Includes: conditions that are coded here
- malignant neoplasm of skin of male genital organs
Official coding guidelines
From the ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027 (CMS and NCHS). Links open the PDF at the right page.
Rules for coding benign and malignant neoplasms: using the Neoplasm Table, sequencing primary and secondary sites, treatment encounters, complications, and current cancer versus personal history.
- Admission/Encounter for treatment of primary site (page 33)
- Admission/Encounter for treatment of secondary site (page 33)
- Coding and sequencing of complications (page 34)
- Primary malignancy previously excised (page 34)
- Admissions/Encounters involving antineoplastic chemotherapy, immunotherapy and radiation therapy (page 35)
- Admission/encounter to determine extent of malignancy (page 36)
- Symptoms, signs, and abnormal findings listed in Chapter 18 associated with neoplasms (page 36)
- Admission/encounter for pain control/management (page 36)
Other codes under C60-C63
Malignant neoplasms of male genital organs (C60-C63)
- C60Malignant neoplasm of penis
- C61Malignant neoplasm of prostate(this code)
- C62Malignant neoplasm of testis
- C63Malignant neoplasm of other and unspecified male genital organs
C61 MS-DRGs
As the principal diagnosis, C61 groups to MS-DRG 715, 716, 722, 723, or 724 (v44.0). Which one applies depends on procedures performed, secondary diagnoses (CC/MCC), and the patient's age and discharge status.
- DRG 715 Male Reproductive System and Other O.R. Procedures for Malignancy with CC/MCC
- DRG 716 Male Reproductive System and Other O.R. Procedures for Malignancy without CC/MCC
- DRG 722 Malignancy, Male Reproductive System with MCC
- DRG 723 Malignancy, Male Reproductive System with CC
- DRG 724 Malignancy, Male Reproductive System without CC/MCC
Related conditions
Grouped by AHRQ's Clinical Classifications Software Refined (CCSR), which sorts every diagnosis code into clinically meaningful categories.
C61 is in Male reproductive system cancers - prostate (NEO039, its default category), with 2 codes. Others in it:
- D07.5 Carcinoma in situ of prostate
Medicare coverage articles listing C61
These 50 Medicare billing and coding articles list C61 as a diagnosis that supports medical necessity for the services they cover. From the CMS Medicare Coverage Database; check your own contractor's article before billing.
- MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers (4 contractors)
- MolDX: Genetic Testing for Hereditary Thrombophilia (4 contractors)
- MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (4 contractors)
- MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (4 contractors)
- MolDX: Next-Generation Sequencing for Solid Tumors (4 contractors)
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer (4 contractors)
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (4 contractors)
- MolDX: Plasma-Based Genomic Profiling in Solid Tumors (4 contractors)
- MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (4 contractors)
- MolDX: Germline testing for use of PARP inhibitors (3 contractors)
And 40 more.
Other codes that refer to C61
Notes on these codes point to C61.
About the condition
Plain-language background from MedlinePlus (National Library of Medicine), not coding guidance.
Prostate Cancer
Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen.
Read more about prostate cancer on MedlinePlusCode history
Valid since FY2016, when ICD-10-CM took effect on October 1, 2015. No changes since.
ICD-9-CM equivalent
Legacy crosswalk from the CMS General Equivalence Mappings (last updated 2018).
- 185 Malignant neoplasm of prostate